Remove 2030 Remove Communication Remove Vaccines
article thumbnail

STAT+: Pharmalittle: We’re reading about Moderna’s RSV vaccine, Aurobindo problems, and more

STAT

We accept all manner of confidential communications and secret dossiers … New diabetes and weight loss drugs may benefit patients undergoing hip replacement without adding to complication risks , Reuters reports, citing preliminary data released at a meeting of orthopedic surgeons. Meanwhile, here are a few tidbits to digest.

Diabetes 275
article thumbnail

Healthier Together and philanthropic ventures in tropical disease

European Pharmaceutical Review

The Kigali Summit on Malaria and NTDs , hosted by His Excellency (HE) Paul Kagame, President of the Republic of Rwanda, on Thursday 23 June 2022, gathered world leaders to commit to ending these devastating diseases by the end of 2030. Europe’s Healthier Together initiative. A guidance document has been released to support these activities.

Vaccines 110
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AMR poses an immediate and widespread threat to global public health: Experts

Express Pharma

Dr Ranga Reddy, President, Infection Control Academy of India said, “AMR poses a threat to various aspects of life, undermining the 2030 Sustainable Development Goals, especially in regions with inadequate sanitation. The concept of healthy aging can be adopted by staying healthy and by vaccinating against the communicable diseases.”

Hospitals 101
article thumbnail

Scientific evidence ‘on demand’? Proceedings from an expert roundtable

pharmaphorum

The ways in which we communicate and consume information are constantly transforming. In 2020, the challenges of the COVID-19 pandemic greatly accelerated the pace of this evolution, with wide-reaching effects on many aspects of medical communications. Q1: What are some ways in which data dissemination has evolved in 2020?

article thumbnail

PharmaShots' Key Highlights of First Quarter 2023

PharmaShots

of the newly combined company The combined companies’ focus is to advance Elicio’s lymph node-targeting amphiphile technology to develop immunotherapies & also focus on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors is currently being evaluated in the P-I trial (AMPLIFY-201) for PDAC and CRC.

article thumbnail

Optimising spend, maximising growth

Express Pharma

This collaboration was vital; it fostered communication among stakeholders, allowing them to swiftly address production hurdles and supply chain uncertainties that arose from both international raw material shortages and unpredictable COVID outbreaks.

Vaccines 104
article thumbnail

GSK, Sanofi and Takeda join AI and robotics push for Singapore biomanufacturing

Pharmaceutical Technology

The Singapore Government has launched Biologics Pharma Innovation Programme Singapore (BioPIPS), which aims to increase the country’s manufacturing capacity for biologics, including recombinant proteins and vaccines. The organizations plan to use data analytics to improve manufacturing processes. Additionally, Merck & Co.

Vaccines 105